AMPK: a novel target for treating hepatic fibrosis

Zhenxing Liang; Tian Li; Shuai Jiang; Jing Xu; Wencheng Di; Zhi Yang; Wei Hu; Yang Yang

doi:10.18632/oncotarget.19376

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

AMPK: a novel target for treating hepatic fibrosis

Zhenxing Liang _, Tian Li, Shuai Jiang, Jing Xu, Wencheng Di, Zhi Yang, Wei Hu and Yang Yang

PDF | HTML | How to cite

Oncotarget. 2017; 8:62780-62792. https://doi.org/10.18632/oncotarget.19376

Metrics: PDF 2516 views | HTML 6073 views | ?

Abstract

Zhenxing Liang1,*, Tian Li2,3,*, Shuai Jiang4,*, Jing Xu1, Wencheng Di5, Zhi Yang3, Wei Hu3 and Yang Yang2,3

1Department of Cardiothoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

2Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, Faculty of Life Sciences, Northwest University, Xi’an 710069, China

3Department of Biomedical Engineering, The Fourth Military Medical University, Xi’an 710032, China

4Department of Aerospace Medicine, The Fourth Military Medical University, Xi’an 710032, China

5Department of Cardiology, Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing 210008, China

*These authors contributed equally to this work

Correspondence to:

Zhenxing Liang, email: [email protected]

Yang Yang, email: [email protected]

Keywords: 5'-AMP-activated protein kinase, hepatic fibrosis, hepatic stellate cells, fatty liver diseases, adiponectin

Received: March 13, 2017 Accepted: July 08, 2017 Published: July 19, 2017

ABSTRACT

Fibrosis is a common process of excessive extracellular matrix (ECM) accumulation following inflammatory injury. Fibrosis is involved in the pathogenesis of almost all liver diseases for which there is no effective treatment. 5'-AMP-activated protein kinase (AMPK) is a cellular energy sensor that can ameliorate the process of hepatic fibrogenesis. Given the existing evidence, we first introduce the basic background of AMPK and hepatic fibrosis and the actions of AMPK in hepatic fibrosis. Second, we discuss the three phases of hepatic fibrosis and potential drugs that target AMPK. Third, we analyze possible anti-fibrosis mechanisms and other benefits of AMPK on the liver. Finally, we summarize and briefly explain the current objections to targeting AMPK. This review may aid clinical and basic research on AMPK, which may be a novel drug candidate for hepatic fibrosis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19376

Publication Alerts

Reviews:

AMPK: a novel target for treating hepatic fibrosis

Abstract